Skip to main content
SpringerLink
Log in

Alzheimer’s Disease

  • Protocol
  • First Online:
Clinical Trials in Neurology

Part of the book series: Neuromethods ((NM,volume 138))

Abstract

This chapter reviews the detailed characteristics of 100 interventional clinical trials in Alzheimer’s disease, published between 2010 and 2015, with the aim of providing conceptual tools for the optimization of design and condition of future clinical trials on this population. For this purpose, the literature review of the 100 most highly cited interventional clinical trials between 2010 and 2015, was performed using the search engine Web of Science. Based on the guidelines by the CONSORT group and the criteria contained in them, relevant practices in these clinical trials are discussed and suggestions are made for the improvement on the design and conduction of further clinical studies in the field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Geldmacher DS, Whitehouse PJ (1997) Differential diagnosis of Alzheimer’s disease. Neurology 48:S2–S9

    Article  CAS  PubMed  Google Scholar 

  2. Prince M, Wimo A, Guerchet M et al (2015) The global impact of dementia. World Alzheimer Report. Alzheimer’s Disease International (ADI), London, pp 3–5

    Google Scholar 

  3. Bernick C, Cummings J, Raman R et al (2012) Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 69:901–905. https://doi.org/10.1001/archneurol.2011.3758

    Article  PubMed  Google Scholar 

  4. The Lancet (2010) Consort 2010. Lancet 375:1136. https://doi.org/10.1016/S0140-6736(10)60456-4

    Article  Google Scholar 

  5. Rinne JO, Brooks DJ, Rossor MN et al (2010) 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372. https://doi.org/10.1016/S1474-4422(10)70043-0

    Article  PubMed  CAS  Google Scholar 

  6. Craft S (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol 69:29. https://doi.org/10.1001/archneurol.2011.233

    Article  PubMed  Google Scholar 

  7. Quinn JF, Raman R, Thomas RG et al (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. JAMA 304:1903–1911. https://doi.org/10.1001/jama.2010.1510

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Laxton AW, Tang-Wai DF, McAndrews MP et al (2010) A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease. Ann Neurol 68:521–534. https://doi.org/10.1002/ana.22089

    Article  PubMed  CAS  Google Scholar 

  9. Feldman HH, Doody RS, Kivipelto M et al (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. Neurology 74:956–964. https://doi.org/10.1212/WNL.0b013e3181d6476a

    Article  PubMed  CAS  Google Scholar 

  10. Salloway S, Sperling R, Fox NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370:322–333. https://doi.org/10.1056/NEJMoa1304839

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Faux NG, Ritchie CW, Gunn A et al (2010) PBT2 rapidly improves cognition in alzheimer’s disease: additional phase II analyses. J Alzheimers Dis 20:509–516. https://doi.org/10.3233/JAD-2010-1390

    Article  PubMed  CAS  Google Scholar 

  12. Doody RS, Thomas RG, Farlow M et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321. https://doi.org/10.1056/NEJMoa1312889

    Article  PubMed  CAS  Google Scholar 

  13. Howard R, McShane R, Lindesay J et al (2012) Donepezil and Memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 366:893–903. https://doi.org/10.1056/NEJMoa1106668

    Article  PubMed  CAS  Google Scholar 

  14. Gold M, Alderton C, Zvartau-Hind M et al (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30:131–146. https://doi.org/10.1159/000318845

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Sato T, Hanyu H, Hirao K et al (2011) Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32:1626–1633. https://doi.org/10.1016/j.neurobiolaging.2009.10.009

    Article  PubMed  CAS  Google Scholar 

  16. Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of Semagacestat for treatment of Alzheimer’s disease. N Engl J Med 369:341–350. https://doi.org/10.1056/NEJMoa1210951

    Article  PubMed  CAS  Google Scholar 

  17. Ostrowitzki S (2012) Mechanism of amyloid removal in patients with Alzheimer disease treated with Gantenerumab. Arch Neurol 69:198. https://doi.org/10.1001/archneurol.2011.1538

    Article  PubMed  Google Scholar 

  18. Siemers ER, Friedrich S, Dean RA et al (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33:67–73. https://doi.org/10.1097/WNF.0b013e3181cb577a

    Article  PubMed  CAS  Google Scholar 

  19. Blennow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69:1002–1010. https://doi.org/10.1001/archneurol.2012.90

    Article  PubMed  Google Scholar 

  20. Winblad B, Andreasen N, Minthon L et al (2012) Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597–604. https://doi.org/10.1016/S1474-4422(12)70140-0

    Article  PubMed  CAS  Google Scholar 

  21. Scheltens P, Kamphuis PJGH, Verhey FRJ et al (2010) Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimer’s Dement 6:1–10.e1. https://doi.org/10.1016/j.jalz.2009.10.003

    Article  CAS  Google Scholar 

  22. Sano MM, Bell KLKL, Galasko DD et al (2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77:556–563

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Rosenberg PB, Drye LT, Martin BK et al (2010) Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18:136–145. https://doi.org/10.1097/JGP.0b013e3181c796eb

    Article  PubMed  PubMed Central  Google Scholar 

  24. Farlow M, Arnold SE, Van Dyck CH et al (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 8:261–271. https://doi.org/10.1016/j.jalz.2011.09.224

    Article  PubMed  CAS  Google Scholar 

  25. Vellas B, Coley N, Ousset PJ et al (2012) Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11:851–859. https://doi.org/10.1016/S1474-4422(12)70206-5

    Article  PubMed  CAS  Google Scholar 

  26. Clare L, Linden DEJ, Woods RT et al (2010) Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatr Psychiatry 18:928–939. https://doi.org/10.1097/JGP.0b013e3181d5792a

    Article  PubMed  Google Scholar 

  27. Dodel R, Rominger A, Bartenstein P et al (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12:233–243. https://doi.org/10.1016/S1474-4422(13)70014-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Galasko DR, Peskind E, Clark CM et al (2012) Antioxidants for Alzheimer disease. Arch Neurol 69:836. https://doi.org/10.1001/archneurol.2012.85

    Article  PubMed  PubMed Central  Google Scholar 

  29. Salloway S, Sperling R, Keren R et al (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77:1253–1262. https://doi.org/10.1212/WNL.0b013e3182309fa5

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Vigen CLP, Mack WJ, Keefe RSE et al (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 168:831–839. https://doi.org/10.1176/appi.ajp.2011.08121844

    Article  PubMed  PubMed Central  Google Scholar 

  31. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68:45–50. https://doi.org/10.1001/archneurol.2010.229

    Article  PubMed  Google Scholar 

  32. Scheltens P, Twisk JWR, Blesa R et al (2012) Efficacy of souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis 31:225–236. https://doi.org/10.3233/JAD-2012-121189

    Article  PubMed  CAS  Google Scholar 

  33. Black RS, Sperling RA, Safirstein B et al (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24:198–203. https://doi.org/10.1097/WAD.0b013e3181c53b00

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Coric V, van Dyck CH, Salloway S et al (2012) Safety and tolerability of the γ-secretase inhibitor Avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430. https://doi.org/10.1001/archneurol.2012.2194

    Article  PubMed  Google Scholar 

  35. Rafii M, Walsh S, Little J et al (2011) A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76:1389–1394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Farlow MR, Salloway S, Tariot PN et al (2010) Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther 32:1234–1251. https://doi.org/10.1016/j.clinthera.2010.06.019

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Weintraub D, Rosenberg PB, Martin BK et al (2010) Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 18:332–340. https://doi.org/10.1097/JGP.0b013e3181cc0333

    Article  PubMed  PubMed Central  Google Scholar 

  38. Douaud G, Refsum H, de Jager CA et al (2013) Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110:9523–9528. https://doi.org/10.1073/pnas.1301816110

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cotelli M, Calabria M, Manenti R et al (2011) Improved language performance in Alzheimer disease following brain stimulation. J Neurol Neurosurg Psychiatry 82:794–797. https://doi.org/10.1136/jnnp.2009.197848

    Article  PubMed  Google Scholar 

  40. Tariot PN, Schneider LS, Cummings J et al (2011) Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 68:853–861. https://doi.org/10.1001/archgenpsychiatry.2011.72

    Article  PubMed  CAS  Google Scholar 

  41. Dysken MW, Sano M, Asthana S et al (2014) Effect of vitamin E and Memantine on functional decline in Alzheimer disease. JAMA 311:353. https://doi.org/10.1001/jama.2013.282834

    Article  Google Scholar 

  42. Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M (2011) Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: two phase 3 studies. Curr Alzheimer Res 8:592–606. BSP/CAR/0168 [pii]

    Article  CAS  PubMed  Google Scholar 

  43. Baker LD, Frank LL, Foster-Schubert K et al (2010) Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer’s disease. J Alzheimers Dis 22:569–579. https://doi.org/10.3233/JAD-2010-100768

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Simmons-Stern NR, Budson AE, Ally BA (2010) Music as a memory enhancer in patients with Alzheimer’s disease. Neuropsychologia 48:3164–3167. https://doi.org/10.1016/j.neuropsychologia.2010.04.033

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sabbagh MN, Agro A, Bell J et al (2011) PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25:206–212. https://doi.org/10.1097/WAD.0b013e318204b550

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Porsteinsson AP, Drye LT, Pollock BG et al (2014) Effect of citalopram on agitation in Alzheimer disease. JAMA 311:682. https://doi.org/10.1001/jama.2014.93

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Del Ser T, Steinwachs KC, Gertz HJ et al (2013) Treatment of Alzheimer’s disease with the GSK-3 inhibitor Tideglusib: a pilot study. J Alzheimers Dis 33:205–215. https://doi.org/10.3233/JAD-2012-120805

    Article  PubMed  CAS  Google Scholar 

  48. Cornelli U (2010) Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener Dis 7:193–202. https://doi.org/10.1159/000295663

    Article  PubMed  CAS  Google Scholar 

  49. Modrego PJ, Fayed N, Errea JM et al (2010) Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 17:405–412. https://doi.org/10.1111/j.1468-1331.2009.02816.x

    Article  PubMed  CAS  Google Scholar 

  50. Akhondzadeh S, Shafiee Sabet M, Harirchian MH et al (2010) A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease. Psychopharmacology 207:637–643. https://doi.org/10.1007/s00213-009-1706-1

    Article  PubMed  CAS  Google Scholar 

  51. McCurry SM, Pike KC, Vitiello MV et al (2011) Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer’s disease: results of a randomized, controlled trial. J Am Geriatr Soc 59:1393–1402. https://doi.org/10.1111/j.1532-5415.2011.03519.x

    Article  PubMed  PubMed Central  Google Scholar 

  52. Alvarez XA, Cacabelos R, Sampedro C et al (2011) Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Eur J Neurol 18:59–68. https://doi.org/10.1111/j.1468-1331.2010.03092.x

    Article  PubMed  CAS  Google Scholar 

  53. Ahmed MA, Darwish ES, Khedr EM et al (2012) Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer’s dementia. J Neurol 259:83–92. https://doi.org/10.1007/s00415-011-6128-4

    Article  PubMed  Google Scholar 

  54. Fox C, Crugel M, Maidment I et al (2012) Efficacy of Memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One 7:e35185. https://doi.org/10.1371/journal.pone.0035185

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Fleisher AS, Truran D, Mai JT et al (2011) Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 77:1263–1271. https://doi.org/10.1212/WNL.0b013e318230a16c

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Maher-Edwards G, Dixon R, Hunter J et al (2011) SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 26:536–544. https://doi.org/10.1002/gps.2562

    Article  PubMed  Google Scholar 

  57. Cummings J, Froelich L, Black SE et al (2012) Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer’s disease. Dement Geriatr Cogn Disord 33:341–353. https://doi.org/10.1159/000340056

    Article  PubMed  CAS  Google Scholar 

  58. Akhondzadeh S, Sabet MS, Harirchian MH et al (2010) ORIGINAL ARTICLE: Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther 35:581–588. https://doi.org/10.1111/j.1365-2710.2009.01133.x

    Article  PubMed  CAS  Google Scholar 

  59. Venturelli M, Scarsini R, Schena F (2011) Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. Am J Alzheimers Dis Other Demen 26:381–388. https://doi.org/10.1177/1533317511418956

    Article  PubMed  Google Scholar 

  60. Stein MS, Scherer SC, Ladd KS, Harrison LC (2011) A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease. J Alzheimers Dis 26:477–484. https://doi.org/10.3233/JAD-2011-110149

    Article  PubMed  CAS  Google Scholar 

  61. Nunes MA, Viel TA, Buck HS et al (2013) Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res 10:104–107

    PubMed  CAS  Google Scholar 

  62. Padala PR, Burke WJ, Shostrom VK et al (2010) Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 18:371–374. https://doi.org/10.1097/JGP.0b013e3181cabcf6

    Article  PubMed  Google Scholar 

  63. Devanand DP, Mintzer J, Schultz SK et al (2012) Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med 367:1497–1507. https://doi.org/10.1056/NEJMoa1114058

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Wahlberg LU, Lind G, Almqvist PM et al (2012) Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg 117:340–347. https://doi.org/10.3171/2012.2.JNS11714

    Article  PubMed  Google Scholar 

  65. Leoutsakos J-MS, Muthen BO, Breitner JCS, Lyketsos CG (2011) Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s disease anti-inflammatory prevention trial. Int J Geriatr Psychiatry. https://doi.org/10.1002/gps.2723

  66. Okahara K, Ishida Y, Hayashi Y et al (2010) Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 34:532–536. https://doi.org/10.1016/j.pnpbp.2010.02.013

    Article  PubMed  CAS  Google Scholar 

  67. Penner J, Rupsingh R, Smith M et al (2010) Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 34:104–110. https://doi.org/10.1016/j.pnpbp.2009.10.007

    Article  PubMed  CAS  Google Scholar 

  68. Vreugdenhil A, Cannell J, Davies A, Razay G (2012) A community-based exercise programme to improve functional ability in people with Alzheimer’s disease: a randomized controlled trial. Scand J Caring Sci 26:12–19. https://doi.org/10.1111/j.1471-6712.2011.00895.x

    Article  PubMed  Google Scholar 

  69. Burns A, Perry E, Holmes C et al (2011) A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord 31:158–164. https://doi.org/10.1159/000324438

    Article  PubMed  CAS  Google Scholar 

  70. Buschert VC, Friese U, Teipel SJ et al (2011) Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild alzheimer’s disease: a pilot study. J Alzheimers Dis 25:679–694. https://doi.org/10.3233/JAD-2011-100999

    Article  PubMed  Google Scholar 

  71. Richard E, Gouw AA, Scheltens P, van Gool WA (2010) Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke 41:554–556. https://doi.org/10.1161/STROKEAHA.109.571281

    Article  PubMed  Google Scholar 

  72. Padala KP, Padala PR, McNeilly DP et al (2012) The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 10:296–302. https://doi.org/10.1016/j.amjopharm.2012.08.002

    Article  PubMed  CAS  Google Scholar 

  73. Yágüez L, Shaw KN, Morris R, Matthews D (2011) The effects on cognitive functions of a movement-based intervention in patients with Alzheimer’s type dementia: a pilot study. Int J Geriatr Psychiatry 26:173–181. https://doi.org/10.1002/gps.2510

    Article  PubMed  Google Scholar 

  74. Wharton W, Baker LD, Gleason CE et al (2011) Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer’s disease: results of a randomized controlled trial. J Alzheimers Dis 26:495–505. https://doi.org/10.3233/JAD-2011-110341

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Cumbo E, Ligori LD (2010) Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy Behav 17:461–466. https://doi.org/10.1016/j.yebeh.2010.01.015

    Article  PubMed  Google Scholar 

  76. Farlow MR, Alva G, Meng X, Olin JT (2010) A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis. Curr Med Res Opin 26:263–269. https://doi.org/10.1185/03007990903434914

    Article  PubMed  CAS  Google Scholar 

  77. Pitkälä KH, Pöysti MM, Laakkonen M-L et al (2013) Effects of the Finnish Alzheimer disease exercise trial (FINALEX). JAMA Intern Med 173:894. https://doi.org/10.1001/jamainternmed.2013.359

    Article  PubMed  Google Scholar 

  78. Hayashi Y, Ishida Y, Inoue T et al (2010) Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry 34:541–545. https://doi.org/10.1016/j.pnpbp.2010.02.016

    Article  PubMed  CAS  Google Scholar 

  79. Waldorff FB, Buss DV, Eckermann A et al (2012) Efficacy of psychosocial intervention in patients with mild Alzheimer’s disease: the multicentre, rater blinded, randomised Danish Alzheimer intervention study (DAISY). BMJ 345:e4693–e4693. https://doi.org/10.1136/bmj.e4693

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Nathan PJ, Boardley RL, Scott N et al (2013) The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer’s disease: a preliminary investigation. Curr Alzheimer Res 10:240–251. https://doi.org/10.2174/1567205011310030003

    Article  PubMed  CAS  Google Scholar 

  81. Kennelly SP, Abdullah L, Paris D et al (2011) Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry 26:1038–1045. https://doi.org/10.1002/gps.2638

    Article  PubMed  CAS  Google Scholar 

  82. Serrano-Pozo A, Vega GL, Lutjohann D et al (2010) Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord 24:220–226. https://doi.org/10.1097/WAD.0b013e3181d61fea

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Nourhashemi F, Andrieu S, Gillette-Guyonnet S et al (2010) Effectiveness of a specific care plan in patients with Alzheimer’s disease: cluster randomised trial (PLASA study). BMJ 340:c2466–c2466. https://doi.org/10.1136/bmj.c2466

    Article  PubMed  PubMed Central  Google Scholar 

  84. Valen-Sendstad A, Engedal K, Stray-Pedersen B et al (2010) Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiatry 18:11–20. https://doi.org/10.1097/JGP.0b013e3181beaaf4

    Article  PubMed  Google Scholar 

  85. Ihl R, Tribanek M, Bachinskaya N (2012) Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761(R) in Alzheimer’s disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry 45:41–46. https://doi.org/10.1055/s-0031-1291217

    Article  PubMed  CAS  Google Scholar 

  86. Alvarez XA, Cacabelos R, Sampedro C et al (2011) Combination treatment in Alzheimer’s disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Curr Alzheimer Res 8:583–591

    Article  CAS  PubMed  Google Scholar 

  87. Shinto L, Quinn J, Montine T et al (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 38:111–120. https://doi.org/10.3233/JAD-130722

    Article  PubMed  CAS  Google Scholar 

  88. Devanand DP, Pelton GH, Cunqueiro K et al (2011) A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Int J Geriatr Psychiatry 26:937–943. https://doi.org/10.1002/gps.2630

    Article  PubMed  CAS  Google Scholar 

  89. Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM et al (2011) Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 15:720–724. https://doi.org/10.1007/s12603-011-0105-6

    Article  PubMed  CAS  Google Scholar 

  90. Lorenzi M, Beltramello A, Mercuri NB et al (2011) Effect of memantine on resting state default mode network activity in Alzheimer’s disease. Drugs Aging 28:205–217. https://doi.org/10.2165/11586440-000000000-00000

    Article  PubMed  CAS  Google Scholar 

  91. Lancioni GE, Singh NN, O’Reilly MF et al (2010) Technology-aided verbal instructions to help persons with mild or moderate Alzheimer’s disease perform daily activities. Res Dev Disabil 31:1240–1250. https://doi.org/10.1016/j.ridd.2010.07.021

    Article  PubMed  Google Scholar 

  92. Landen JW, Zhao Q, Cohen S et al (2013) Safety and pharmacology of a single intravenous dose of Ponezumab in subjects with mild-to-moderate Alzheimer disease. Clin Neuropharmacol 36:14–23. https://doi.org/10.1097/WNF.0b013e31827db49b

    Article  PubMed  CAS  Google Scholar 

  93. Kume K, Hanyu H, Sakurai H et al (2012) Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int 12:207–214. https://doi.org/10.1111/j.1447-0594.2011.00746.x

    Article  PubMed  Google Scholar 

  94. Frölich L, Ashwood T, Nilsson J, Eckerwall G (2011) Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer’s disease: a phase IIb dose-finding study. J Alzheimers Dis 24:363–374. https://doi.org/10.3233/JAD-2011-101554

    Article  PubMed  CAS  Google Scholar 

  95. Winblad B, Giacobini E, Frölich L et al (2010) Phenserine efficacy in Alzheimer’s disease. J Alzheimers Dis 22:1201–1208. https://doi.org/10.3233/JAD-2010-101311

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Kurz A, Thöne-Otto A, Cramer B et al (2012) CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial. Alzheimer Dis Assoc Disord 26:246–253. https://doi.org/10.1097/WAD.0b013e318231e46e

    Article  PubMed  Google Scholar 

  97. Uenaka K, Nakano M, Willis BA et al (2012) Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol 35:25–29. https://doi.org/10.1097/WNF.0b013e31823a13d3

    Article  PubMed  CAS  Google Scholar 

  98. Roach KKE, Tappen RMR, Kirk-Sanchez N et al (2011) A randomized controlled trial of an activity specific exercise program for individuals with Alzheimer disease in long-term care settings. J Geriatr Phys Ther 34:50–56. https://doi.org/10.1519/JPT.0b013e31820aab9c.A

    Article  PubMed  PubMed Central  Google Scholar 

  99. Farlow M, Veloso F, Moline M et al (2011) Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease. BMC Neurol 11:57. https://doi.org/10.1186/1471-2377-11-57

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Niu Y-X, Tan J-P, Guan J-Q et al (2010) Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer’s disease: a randomized controlled trial. Clin Rehabil 24:1102–1111

    Article  PubMed  Google Scholar 

  101. Rabey JM, Dobronevsky E, Aichenbaum S et al (2013) Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer’s disease: a randomized, double-blind study. J Neural Transm 120:813–819. https://doi.org/10.1007/s00702-012-0902-z

    Article  PubMed  Google Scholar 

  102. Claxton A, Baker LD et al (2013) Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer’s disease. J Alzheimers Dis 35:789–797. https://doi.org/10.3233/JAD-122308.Sex

    Article  PubMed  PubMed Central  Google Scholar 

  103. Sakurai H, Hanyu H, Sato T et al (2013) Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer’s disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 13:90–97. https://doi.org/10.1111/j.1447-0594.2012.00866.x

    Article  PubMed  Google Scholar 

  104. Munro CA, Longmire CF, Drye LT et al (2012) Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry 20:1036–1044. https://doi.org/10.1097/JGP.0b013e31826ce4c5

    Article  PubMed  PubMed Central  Google Scholar 

  105. Rennie D (2001) CONSORT revised—improving the reporting of randomized trials. JAMA 285:2006–2007

    Article  CAS  PubMed  Google Scholar 

  106. Cummings J, Gould H, Zhong K (2012) Advances in designs for Alzheimer’s disease clinical trials. Am J Neurodegener Dis 1:205–216

    PubMed  PubMed Central  Google Scholar 

  107. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708–720. https://doi.org/10.1093/jnci/djp079

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. FDA (1994) European Medicines Agency, ICH Topic E4, Dose response information to support drug registration, Reference No. CPMP/ICH/378/95, Published May 1994. Guidel Ind 2–4

    Google Scholar 

  109. Benedetti F, Mayberg HS, Wager TD et al (2005) Neurobiological mechanisms of the placebo effect. J Neurosci 25:10390–10402. https://doi.org/10.1523/JNEUROSCI.3458-05.2005

    Article  PubMed  CAS  Google Scholar 

  110. Hróbjartsson A, Gøtzsche PC (2004) Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 256:91–100. https://doi.org/10.1111/j.1365-2796.2004.01355.x

    Article  PubMed  Google Scholar 

  111. Hoffman GA, Harrington A, Fields HL (2005) Pain and the placebo: what we have learned. Perspect Biol Med 48:248–265. https://doi.org/10.1353/pbm.2005.0054

    Article  PubMed  Google Scholar 

  112. Kamper SJ, Machado LAC, Herbert RD et al (2008) Trial methodology and patient characteristics did not influence the size of placebo effects on pain. J Clin Epidemiol 61:256–260. https://doi.org/10.1016/j.jclinepi.2007.03.017

    Article  PubMed  Google Scholar 

  113. Turner JA, Deyo RA, Loeser JD et al (1994) The importance of placebo effects in pain treatment and research. JAMA 271:1609–1614. https://doi.org/10.1001/jama.1994.03510440069036

    Article  PubMed  CAS  Google Scholar 

  114. Salloway S, Sperling R, Gilman S et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061–2070. https://doi.org/10.1212/WNL.0b013e3181c67808

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  115. Cole SR, Stuart EA (2010) Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial. Am J Epidemiol 172:107–115. https://doi.org/10.1093/aje/kwq084

    Article  PubMed  PubMed Central  Google Scholar 

  116. Rothwell PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365:82–93. https://doi.org/10.1016/S0140-6736(04)17670-8

    Article  PubMed  Google Scholar 

  117. Shapiro SH, Weijer C, Freedman B (2000) Reporting the study populations of clinical trials clear transmission or static on the line? J Clin Epidemiol 53:973–979. https://doi.org/10.1016/S0895-4356(00)00227-4

    Article  PubMed  CAS  Google Scholar 

  118. Ng T-P, Niti M, Chiam P-C, Kua E-H (2007) Ethnic and educational differences in cognitive test performance on mini-mental state examination in Asians. Am J Geriatr Psychiatry 15:130–139. https://doi.org/10.1097/01.JGP.0000235710.17450.9a

    Article  PubMed  Google Scholar 

  119. Eriksdotter-Jönhagen M, Linderoth B, Lind G et al (2012) Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 33:18–28. https://doi.org/10.1159/000336051

    Article  PubMed  CAS  Google Scholar 

  120. Shuster JJ (1991) Median follow-up in clinical trials. J Clin Oncol 9:191–192

    Article  CAS  PubMed  Google Scholar 

  121. FDA, (Office of Combination Products in the Office of the Commissioner (OCP), the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER) and the C for D and RH (CDRH)) (2011) Classification of products as drugs and devices & additional product classification issues. Guidance for Industry. FDA. p. 3

    Google Scholar 

  122. Aronson JK (2005) Biomarkers and surrogate endpoints. Br J Clin Pharmacol 59:491–494. https://doi.org/10.1111/j.1365-2125.2005.02435.x

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  123. Charles P, Giraudeau B, Dechartres A et al (2009) Reporting of sample size calculation in randomised controlled trials: review. BMJ 338:b1732. https://doi.org/10.1136/bmj.b1732

    Article  PubMed  PubMed Central  Google Scholar 

  124. Abdulatif M, Mukhtar A, Obayah G, Hardman JG (2015) Pitfalls in reporting sample size calculation in randomized controlled trials published in leading anaesthesia journals: a systematic review. Br J Anaesth 115:699–707. https://doi.org/10.1093/bja/aev166

    Article  PubMed  CAS  Google Scholar 

  125. Chalmers TC, Celano P, Sacks HS, Smith H (1983) Bias in treatment assignment in controlled clinical trials. N Engl J Med 309:1358–1361. https://doi.org/10.1056/NEJM198312013092204

    Article  PubMed  CAS  Google Scholar 

  126. Dumville JC, Hahn S, Miles JN, Torgerson DJ (2006) The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials 27:1–12. https://doi.org/10.1016/j.cct.2005.08.003

    Article  PubMed  CAS  Google Scholar 

  127. Hey SP, Kimmelman J (2014) The questionable use of unequal allocation in confirmatory trials. Neurology 82:77–79. https://doi.org/10.1212/01.wnl.0000438226.10353.1c

    Article  PubMed  PubMed Central  Google Scholar 

  128. Ard MC, Edland SD (2011) Power calculations for clinical trials in Alzheimer’s disease. J Alzheimers Dis 26:369–377. https://doi.org/10.3233/JAD-2011-0062

    Article  PubMed  PubMed Central  Google Scholar 

  129. Vozdolska R, Sano M, Aisen P, Edland SD (2009) The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials 6:126–132. https://doi.org/10.1177/1740774509103485

    Article  PubMed  PubMed Central  Google Scholar 

  130. Moscucci M, Byrne L, Weintraub M, Cox C (1987) Blinding, unblinding, and the placebo effect: an analysis of patients’ guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther 41:259–265

    Article  CAS  PubMed  Google Scholar 

  131. Atreja A, Bellam N, Levy SR (2005) Strategies to enhance patient adherence: making it simple. MedGenMed 7(1):4. https://doi.org/10.2147/RMHP.S19801

    Article  PubMed  PubMed Central  Google Scholar 

  132. Rosenberg J, Bauchner H, Backus J et al (2014) The new ICMJE recommendations. Indian J Med Microbiol 32:219–220. https://doi.org/10.4103/0255-0857.136545

    Article  PubMed  Google Scholar 

  133. Hoffmann TC, Thomas ST, Shin PNH, Glasziou PP (2014) Cross-sectional analysis of the reporting of continuous outcome measures and clinical significance of results in randomized trials of non-pharmacological interventions. Trials 15:362. https://doi.org/10.1186/1745-6215-15-362

    Article  PubMed  PubMed Central  Google Scholar 

  134. Cheng J, Edwards LJ, Maldonado-Molina MM et al (2010) Real longitudinal data analysis for real people: building a good enough mixed model. Stat Med 29:504–520. https://doi.org/10.1002/sim.3775

    Article  PubMed  PubMed Central  Google Scholar 

  135. Ioannidis JPA, Evans SJW, Gøtzsche PC et al (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:781–788. https://doi.org/10.7326/0003-4819-141-10-200411160-00009

    Article  PubMed  Google Scholar 

  136. Gandhi M, Ameli N, Bacchetti P et al (2005) Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS 19:1885–1896. https://doi.org/10.1097/01.aids.0000189866.67182.f7

    Article  PubMed  Google Scholar 

  137. Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746. https://doi.org/10.1016/S1474-4422(07)70178-3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA

    Aura M. Hurtado-Puerto, Cristina Russo & Felipe Fregni

Authors
  1. Aura M. Hurtado-Puerto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe Fregni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felipe Fregni .

Editor information

Editors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Felipe Fregni

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Hurtado-Puerto, A.M., Russo, C., Fregni, F. (2018). Alzheimer’s Disease. In: Fregni, F. (eds) Clinical Trials in Neurology. Neuromethods, vol 138. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7880-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7880-9_9

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7879-3

  • Online ISBN: 978-1-4939-7880-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation